Nonspecific phosphodiesterase inhibition attenuates liver injury in acute endotoxemia

Surgical Infections

Volumn 6, Issue 1, 2005, Pages 73-85

  Coimbra, Raul ^a   Porcides, Rafael Dib ^a   Melbostad, Heidi ^a   Loomis, William ^a   Tobar, Maria ^a   Hoyt, David B ^a   Wolf, Paul ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BACTERIUM LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MYELOPEROXIDASE; NITRITE; PENTOXIFYLLINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; SODIUM CHLORIDE; SYNAPTOTAGMIN; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; ENDOTOXEMIA; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KUPFFER CELL; LIVER HEMORRHAGE; LIVER INJURY; LIVER PROTECTION; LIVER SINUSOID; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; STATISTICAL SIGNIFICANCE;

ALANINE TRANSAMINASE; ANIMALS; ASPARTATE AMINOTRANSFERASES; ENDOTOXEMIA; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; LIVER DISEASES; MALE; NF-KAPPA B; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PENTOXIFYLLINE; PEROXIDASE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 19044389392     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2005.6.73     Document Type: Article

References (46)

1. Maeshima K, Takahashi T, Nakahira K, et al. A protective role of interleukin-11 on hepatic injury in acute endotoxemia. Shock 2004;21:134-138.
2. Doi F, Goya T, Torisu M. Potential role of hepatic macrophages in neutrophil-mediated liver injury in rats with sepsis. Hepatology 1993;17:1086-1094.
3. Tran-Thi TA, Decker K, Baeuerle PA. Differential activation of transcription factors NF-kappa B and AP-1 in rat liver macrophages. Hepatology 1995;22:613-619.
4. Sullivan GW, Carper HT, Novick WJ, et al. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor-α on neutrophil function by pentoxifylline. Infect Immunol 1988;56:1722-1729.
5. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990;31:171-181.
6. Michetti C, Coimbra R, Hoyt DB, et al. Pentoxifylline reduces acute lung injury in chronic endotoxemia. J Surg Res 2003;115:92-99.
7. Thiel M, Bardenheuer H, Poch G, et al. Pentoxifylline does not act via adenosine receptors in the inhibition of the superoxide anion production of human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;180:53-58.
8. Josaki K, Contrino J, Kristie J, et al. Pentoxifylline-induced modulation of human leukocyte function in vitro. Am J Pathol 1990;136:623-630.
9. Currie MS, Rao KMK, Padmanabhan J, et al. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990;47:244-250.
10. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A double-blind, placebo-controlled trial. Gastroenterology 2000;119: 1637-1648.
11. Bacher A, Mayer N, Klimscha W, Oismuller C, Steltzer H, Boldt J, et al. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients. Crit Care Med. 2001; 29:952-958.
12. Schroder J, Staubach KH, Stuber F, Zabel P. Pentoxifylline as adjuvant therapy of multiple organ failure. Langenbecks Arch Surg 1998;115(Suppl I):461-465.
13. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 1996;155: 404-409.
14. Lauterbach R, Pawlik D, Kowalczyk D, et al. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med 1999;27:807-814.
15. Bultler J, Baigrie RJ, Parker D, et al. Systemic inflammatory responses to cardiopulmonary bypass: A study on the effects of pentoxifylline. Respir Med 1993;87:285-288.
16. Staubach KH, Schroder J, Stuber F, et al. Effect of pentoxifylline in severe sepsis: Results of a randomized, double-blind, placebo-controlled study. Arch Surg 1998;133:94-100.
17. Bacher A, Mayer N, Klimscha W, et al. Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 1997; 25:795-800.
18. Zeni F, Pain P, Vindimian M, Gay JP, et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996;24:207-214.
19. Oismuller C, Mayer N, Micksche M, et al. In vivo modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Shock 1995;4:161-165.
20. Boldt J, Muller M, Heesen M, et al. Does long-term continuous administration of pentoxifylline affect platelet function in the critically ill patient? Intensive Care Med 1996;22:644-650.
21. Boldt J, Muller M, Heyn S, et al. Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients. Crit Care Med 1996;24:940-946.
22. Sneed RA, Grimes SD, Schultze AE, et al. Bacterial endotoxin enhances the hepatotoxicity of allyl alcohol. Toxicol Appl Pharmacol 1997;144:77-87.
23. Suntres ZE. Prophylaxis against lipopolysaccharide-induced liver injuries by lipoic acid in rats. Pharmacol Res 2003;48:585-591.
24. Aono K, Isobe K, Kinchi K, et al. In vitro and in vivo expression of inducible nitric oxide synthase during experimental endotoxemia: Involvement of other cytokines. J Cell Biochem 1997;65:349-358.
25. Jaeschke H, Farhood A, Fisher MA, et al. Sequestration of neutrophils in the hepatic vasculature during endotoxemia is independent of beta 2 integrins and intercellular adhesion molecule-1. Shock 1996;6:351-356.
26. Hasegawa T, Sakurai K, Kambayashi Y, et al. Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: Involvement of superoxide and tumor necrosis factor-α from hepatic macrophages. Surgery 2003;134:818-826.
27. Coimbra R, Melbostad H, Hoyt D. Effects of phosphodiesterase inhibition on the inflammatory response after shock: Role of pentoxifylline. J Trauma 2004;56:442-449.
28. Jaeschke H, Smith CW, Clemens MG, et al. Mechanisms of inflammatory liver injury: Adhesion molecules and cytotoxity of neutrophils. Toxicol Appl Pharmacol 1996;139:213-226.
29. Hewett JA, Roth RA. Hepatic and extrahepatic pathology of bacterial lipopolysaccharides. Pharmacol Rev 1993;45:381-441.
30. Tellez-Gil L, Mansilla-Rosello A, Colado-Torres A, et al. Effect of pretreatment with interleukin-1 on inflammatory infiltrates and tissue damage after experimental endotoxic challenge. Crit Care Med 2002; 30:1820-1825.
31. Bustamante J, Lodge JK, Marcocci L, et al. α-Lipoic acid in liver metabolism and disease. Free Radic Biol Med 1998;24:1023-1039.
32. Madhani M, Barchowsky A, Klei L, et al. Antibacterial peptide PR-39 affects local nitric oxide and preserves tissue oxygenation in the liver during septic shock. Biochem Biophys Acta 2002;1588:232-240.
33. Li J, Quan N, Bray TM. Supplementation of N-acetylcysteine normalizes lipopolysaccharide-induced nuclear factor-kappa B activation and proinflammatory cytokine production during early rehabilitation of protein malnourished mice. J Nutr 2002;132:3286-3292.
34. Choi SH, Kim SG. Lipopolysaccharide inhibition of rat hepatic microsomal epoxide hydrolase and glutathione S-transferase gene expression irrespective of nuclear factor-kappa B activation. Biochem Pharmacol 1998;56:1427-1436.
35. Neuschwander-Terri BA, Bellezo JM, Britton RS, et al. Thiol regulation of endotoxin-induced release of tumor necrosis factor-alpha from isolated rat Kupffer cells. Biochem J 1996;320:1005-1010.
36. Mandi Y, Nagy Z, Ocsovski I, et al. Effects of tumor necrosis factor and pentoxifylline on ICAM-1 expression on human polymorphonuclear granulocytes. Int Arch Allergy Immunol 1997;114:329-335.
37. Marzi I, Maier M, Herzog C, et al. Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat. J Trauma 1996;40:90-96.
38. Muller JM, Vollmar B, Menger MD. Pentoxifylline reduces venular leukocyte adherence ("reflow paradox") but not microvascular "no reflow" in hepatic ischemia/reperfusion. J Surg Res 1997;71:1-6.
39. Ruetten H, Southan GJ, Abate A, et al. Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br J Pharmacol 1996; 118:261-270.
40. Curran RD, Billiar TR, Stuehr DJ, et al. Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells. J Exp Med 1989;170:1769-1774.
41. Hsu CM, Wang JS, Liu CH, et al. Kupffer cells protect liver from ischemia-reperfusion injury by inducible nitric oxide synthase-dependent mechanism. Shock 2002;17:280-285.
42. Alexander B. The role of nitric oxide in hepatic metabolism. Nutrition 1998;14:376-390.
43. Taylor BS, Alarcon LH, Billiar TR. Review: Inducible nitric oxide synthase in the liver: Regulation and function. Biochemistry (Mosc) 1998;63:766-781.
44. 2+-independent nitric oxide synthases. FEBS Lett 1991;29:145-149.
45. Chen C, Zamora R, Zuckerbraun B, et al. Role of nitric oxide in liver injury. Curr Molec Med 2003;3:519-526.
46. Ou J, Carlos TM, Watkins SC, et al. Differential effects of nonselective nitric oxide synthase (NOS) and selective inducible NOS inhibition on hepatic necrosis, apoptosis, ICAM-1 expression, and neutrophil accumulation during endotoxemia. Nitric Oxide 1997;1: 404-416.